Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk
Wen-Hsi Lan, Ting‐Yu Lin, Jia-Ai Yeh, Chun‐Lung Feng, Jun‐Te Hsu, Hwai‐Jeng Lin, Chia‐Jung Kuo, Chih‐Ho Lai
Abstract
Diabetes mellitus is associated with a high risk of developing gastric cancer (GC). Metformin, which is conventionally used to treat type 2 diabetes, induces AMP-activated protein kinase signaling and suppresses gluconeogenesis. Recent studies have reported that metformin is associated with beneficial effects in cancer prevention and treatment owing to its anti-tumor effects. This makes metformin a potential medication for GC therapy. However, contradicting reports have emerged regarding the efficacy of metformin in reducing the risk of GC. This review summarizes the impact of metformin on mitigating GC risk by analyzing clinical databases. The mechanism underlying the anti-tumor effect of metformin on GC is also discussed.